25 Or More Amino Acid Residues In Defined Sequence Patents (Class 530/324)
-
Patent number: 11684674Abstract: The invention provides formulations for oral delivery of a therapeutic agent wherein the formulation comprises a kappa opioid receptor agonist and an absorption enhancer, the absorption enhancer includes a medium chain fatty acid or a salt of a medium chain fatty acid; and a medium chain fatty acid glyceride. The kappa opioid receptor agonist may be embedded in an oligosaccharide, such as trehalose. Also provided are capsules containing the oral formulations of the kappa opioid receptor agonists and the absorption enhancer of the invention and methods use of these formulations for the prophylaxis and treatment of variety of kappa opioid receptor-associated diseases and conditions such as pain, pruritus and inflammation; the method comprising administering to the mammal the formulation comprising the kappa opioid receptor agonist and an absorption enhancer.Type: GrantFiled: April 28, 2021Date of Patent: June 27, 2023Assignee: Cara Therapeutics, Inc.Inventors: Bryan R. Wilson, Stephen J. O'Connor
-
Patent number: 11660347Abstract: The present disclosure provides a siRNA for inhibiting the expression of apolipoprotein C3 (ApoC3) gene, and a pharmaceutical composition and a conjugate comprising the siRNA; wherein each nucleotide in the siRNA is independently a modified nucleotide, and the siRNA comprises a sense strand and an antisense strand; the sense strand comprises a nucleotide sequence A, the nucleotide sequence A having the same length as the nucleotide sequence as represented by SEQ ID NO:1 with no more than 3 nucleotide differences; the antisense strand comprises a nucleotide sequence B, the nucleotide sequence B having the same length as the nucleotide sequence as represented by SEQ ID NO:2 with no more than 3 nucleotide differences.Type: GrantFiled: November 29, 2018Date of Patent: May 30, 2023Assignee: SUZHOU RIBO LIFE SCIENCE CO., LTD.Inventors: Hongyan Zhang, Shan Gao, Daiwu Kang
-
Patent number: 11660550Abstract: There is disclosed a relatively simple method to increase the performance of surface localised multi-valent affinity ligands whose target's isoelectric pH differs significantly from the ligand's optimal target-binding pH. This situation can result in ligand binding of target affecting local pH and subsequent binding of more target. Increasing the buffering capacity of the ligand via recombinant or other addition of charge groups to the ligand is expected to partially offset such effects, leading to enhanced binding capacity as well as possible secondary favourable alterations in regard to ligand elution pH, and non-specific surface binding of non-target proteins.Type: GrantFiled: March 6, 2018Date of Patent: May 30, 2023Assignee: JMVA BIOTECH ABInventor: James M. Van Alstine
-
Patent number: 11643443Abstract: Methods of making engineered protein-based materials, nanofibers, and biofilms from bacterial amyloid-based structures that are capable of mediating long-range electron transport are provided.Type: GrantFiled: November 18, 2016Date of Patent: May 9, 2023Assignee: President and Fellows of Harvard CollegeInventors: Neel Satish Joshi, Noémie-Manuelle Dorval Courchesne
-
Patent number: 11633482Abstract: A compound for forming a conjugate with an active agent such as an oligonucleotide having a structure represented by Formula (321). The present disclosure also provides a corresponding conjugate. The conjugate of the present disclosure can specifically target hepatocytes, thereby effectively solve the problems associated with delivery of oligonucleotide drugs in vivo, and have low toxicity and excellent delivery efficiency while maintaining high stability for the delivered oligonucleotide.Type: GrantFiled: November 29, 2018Date of Patent: April 25, 2023Assignee: SUZHOU RIBO LIFE SCIENCE CO., LTD.Inventors: Hongyan Zhang, Zhiwei Yang, Liqiang Cao, Liangyi Wan
-
Patent number: 11608359Abstract: The present invention provides Larazotide derivative compositions that resist protease degradation, and in various embodiments, do not demonstrate an inverse dose response, and/or can be delivered at higher doses without loss of potency or efficacy, thereby allowing improved therapy and more desirable dosing schedules.Type: GrantFiled: February 25, 2019Date of Patent: March 21, 2023Assignee: 9 Meters Biopharma, Inc.Inventors: Jay P. Madan, Balasingham Radhakrishnan, Sandeep Laumas, Christopher Prior
-
Patent number: 11608414Abstract: The present invention provides peptoid polymers and salts thereof that comprise hydrophobic and polar peptoid monomers and are capable of reducing or inhibiting the formation of ice crystals at sub 0° C. temperatures. Also provided are peptoid-peptide hybrids and salts thereof comprising the peptoid polymers provided herein. The peptoid polymers, peptoid-peptide hybrids, and salts thereof provided herein are useful for making cryoprotectant solutions. The peptoid polymers, peptoid-peptide hybrids, salts thereof, and cryoprotectant solutions provided herein are useful for making antifreeze solutions, frozen food products, and cosmetic care products. Also provided herein are methods for preserving a tissue, an organ, a cell, or a biological macromolecule using the compositions described herein.Type: GrantFiled: September 26, 2019Date of Patent: March 21, 2023Assignee: X-THERMA, INC.Inventor: Xiaoxi Wei
-
Patent number: 11608511Abstract: Compositions and methods concern the sequence modification of an endogenous genomic DNA region. Certain aspects relate to a method for site-specific sequence modification of a target genomic DNA region in cells comprising: contacting the cells with an activating composition; transfecting the cells with a transfection composition comprising (a) donor DNA and (b) a DNA digesting agent; wherein the donor DNA comprises: (i) a homologous region comprising nucleic acid sequence homologous to the target genomic DNA region; and (ii) a sequence modification region; and wherein the genomic DNA sequence is modified specifically at the target genomic DNA region.Type: GrantFiled: April 13, 2016Date of Patent: March 21, 2023Assignee: MaxCyte, Inc.Inventors: Linhong Li, Madhusudan Peshwa
-
Patent number: 11578110Abstract: The present disclosure provides peptides, or variants or analogs thereof, with between 8 and 30 amino acids, having growth factor receptor-binding capability, wherein the RMSD value of the structure coordinates of said peptide, variant or analog thereof with respect to PEPREF is 2.45 ? (Angstroms) or less.Type: GrantFiled: August 25, 2016Date of Patent: February 14, 2023Assignee: HISTIDE AGInventor: Omar F. Zouani
-
Patent number: 11564388Abstract: The present invention provides methods for cryopreserving a population of cells with improved cell viability. In some aspects, the method comprises contacting a population of cells with a peptoid polymer comprising one or more polar peptoid monomers, e.g., formulated in a cryoprotectant solution, and cooling the population of cells at a temperature of from 0° C. to about ?20° C. for a time period of at least about 3 hours to produce a population of supercooled cells. The supercooling methods of the present invention provide excellent post-thaw cell survival and recovery. In certain embodiments, the population of cells is present in a tissue or an organ that is cryopreserved by performing the supercooling methods of the present invention.Type: GrantFiled: September 26, 2019Date of Patent: January 31, 2023Assignee: X-THERMA, INC.Inventor: Xiaoxi Wei
-
Patent number: 11566082Abstract: An Fc-binding polypeptide of improved alkali stability, comprising a mutant of an Fc-binding domain of Staphylococcus Protein A (SpA), as defined by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO 26 or SEQ ID NO 27, wherein at least the alanine residue at the position corresponding to position 42 in SEQ ID NO:4-7 has been mutated to arginine and/or wherein at least the aspartic acid residue at the position corresponding to position 37 in SEQ ID NO:4-7 has been mutated to glutamic acid.Type: GrantFiled: November 11, 2015Date of Patent: January 31, 2023Assignee: Cytiva BioProcess R&D ABInventors: Gustav Rodrigo, Tomas Bjorkman, Mats Ander
-
Patent number: 11535654Abstract: The present invention addresses the problem of providing: a fusion protein or conjugated protein having excellent cell membrane permeability, containing a partial peptide derived from human, and suitable for intracellular delivery; an intracellular delivery carrier comprising such a fusion protein or conjugated protein; a partial peptide; a cell membrane permeation enhancer comprising the partial peptide; DNA; and a vector. The fusion protein or conjugated protein has a partial peptide comprising at least seven consecutive amino acid residues of an amino acid sequence encoded by a predetermined DNA, and a ligand directly or indirectly bound to the partial peptide and having the capability of binding to cell surfaces. The ligand is preferably an antibody. The intracellular delivery carrier comprises the fusion protein or conjugated protein. The cell membrane permeation enhancer comprises the partial peptide.Type: GrantFiled: June 2, 2016Date of Patent: December 27, 2022Assignee: Keio UniversityInventors: Kei Sudo, Keisuke Niikura, Nobuhide Doi
-
Patent number: 11524984Abstract: A recombinant spider silk protein, consisting of no more than 800 amino acids, comprising a set of domains arranged according to the formula (NT)-REP-CT, wherein: the optional NT-domain, if present, comprises a sequence of 100 to 160 amino-acid residues derived from the N-terminal domain of a spider silk protein; the REP-domain comprises a sequence of 30 to 600 amino acid residues derived from the repetitive segment of a spider silk protein; and the CT-domain comprises a sequence of 70 to 120 amino acid residues derived from the C-terminal domain of a spider silk protein selected from: a sequence of 72 to 110 amino acid residues derived from the C-terminal domain of a spider silk protein, wherein the sequence comprises at least 7 residues independently selected from K, R, E and D; a sequence having at least 85% identity to SEQ ID NO: 15 or any one of SEQ ID NOs: 62-65 or 67-73; and a sequence having at least 70% identity to SEQ ID NOs: 64 or any one of SEQ ID NOs: 62-65 or 67-73, wherein the sequence compriseType: GrantFiled: June 29, 2017Date of Patent: December 13, 2022Assignee: SPIBER TECHNOLOGIES ABInventors: Anna Rising, Jan Johansson, Marlene Andersson
-
Patent number: 11524986Abstract: Compositions and methods for the inhibiting human growth hormone (hGH), and treating or preventing hGH-mediated disorders, using a S1H peptide having the amino acid sequence of [SEQ ID NO: 1], or a variant thereof, are described.Type: GrantFiled: July 10, 2019Date of Patent: December 13, 2022Assignee: Ohio UniversityInventors: Justin M. Holub, John J. Kopchick, Reetobrata Basu
-
Patent number: 11484521Abstract: The present application provides, inter alia, a compound of Formula (I): or a pharmaceutically acceptable salt thereof, and methods of use of the compound of Formula (I) for treatment and prevention of cyanide poisoning.Type: GrantFiled: April 12, 2018Date of Patent: November 1, 2022Assignees: The General Hospital Corporation, The Regents of the University of CaliforniaInventors: Randall Peterson, Robert Gerszten, Anjali Nath, Calum MacRae, Gerry Boss, Matt Brenner, Sari Brenner Mahon
-
Patent number: 11446356Abstract: Engineered peptides that bind with high affinity (low equilibrium dissociation constant (Kd)) to the cell surface receptors of fibronectin (?5?1) or vitronectin (?v?3 and ?v?5 integrins) are disclosed as useful as imaging tissue. These peptides are based on a molecular scaffold into which a subsequence containing the RGD integrin-binding motif has been inserted. The subsequence (RGD mimic) comprises about 9-13 amino acids, and the RGD contained within the subsequence can be flanked by a variety of amino acids, the sequence of which was determined by sequential rounds of selection (in vitro evolution). The molecular scaffold is preferably based on a knottin, e.g., EETI (Trypsin inhibitor 2 (Trypsin inhibitor II) (EETI-II) [Ecballium elaterium (Jumping cucumber)], AgRP (Agouti-related protein), and Agatoxin IVB, which peptides have a rigidly defined three-dimensional conformation. It is demonstrated that EETI tolerates mutations in other loops and that the present peptides may be used as imaging agents.Type: GrantFiled: February 28, 2020Date of Patent: September 20, 2022Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Jennifer R. Cochran, Richard H. Kimura, Aron M. Levin
-
Patent number: 11413327Abstract: A method of alleviating joint pain in a patient comprising evaluating the patient's joint pain when undergoing motions associated stress to the joint, and injecting the patient with a peptide of SEQ ID No. 1, and thereafter evaluating the patient's joint pain when undergoing the same motion.Type: GrantFiled: October 30, 2020Date of Patent: August 16, 2022Assignee: ORTHOTROPHIX, INC.Inventors: Yoshinari Kumagai, Dawn McGuire, Meghan Miller, David Rosen
-
Patent number: 11389505Abstract: A method of alleviating joint pain in a patient comprising evaluating the patient's joint pain when undergoing motions associated stress to the joint, and injecting the patient with a peptide of SEQ ID No. 1, and thereafter evaluating the patient's joint pain when undergoing the same motion.Type: GrantFiled: October 9, 2020Date of Patent: July 19, 2022Assignee: ORTHOTROPHIX, INC.Inventors: Yoshinari Kumagai, Dawn McGuire, Meghan Miller, David Rosen
-
Patent number: 11382968Abstract: Provided in the present disclosure are immunogenic compounds, pharmaceutical formulations thereof and their use for inducing a protective immune response against 2019 novel coronavirus (SARS-CoV-2) infection and variants in a mammal.Type: GrantFiled: June 9, 2021Date of Patent: July 12, 2022Assignee: Altimmune Inc.Inventors: Bertrand Victor Gilbert Georges, M. Scot Roberts
-
Patent number: 11358994Abstract: The disclosure provides for new epidermal growth factor (EGF)-based reagents that have been modified by fatty acid conjugation. Method of using such agents to treatment Short Bowel Syndrome (SBS) are also described.Type: GrantFiled: July 25, 2018Date of Patent: June 14, 2022Assignee: Saint Louis UniversityInventors: Marvin J. Meyers, David C. Wood, Stacy D. Arnett, Matthew P. Yates, Peter G. Ruminski
-
Patent number: 11319341Abstract: Doxorubicin derivatives for targeted activation by Legumain, its preparation method and use. The doxorubicin derivatives are obtained by condensation between the amino group of compound A and the carboxyl group of compound B and have the following structure: compounds A and B have the following structures, respectively: wherein R3 in compound B is Leu or absent; R4 is any one amino acid selected from the group consisting of Ala and Thr; R5 is any one amino acid selected from the group consisting of Ala, Thr and Asn; R6 is wherein n=1-20; or wherein R7 is substituted or unsubstituted, linear or branched, saturated or unsaturated C1-C20 fatty hydrocarbon, or substituted or unsubstituted C6-C20 aromatic hydrocarbon. The doxorubicin derivatives of the present invention are specifically tumor-targeted and have a long in vivo metabolic half-life, as compared with doxorubicin. They exhibit an efficient and safe anti-tumor effect and could be used to prepare an anti-tumor drug.Type: GrantFiled: February 20, 2020Date of Patent: May 3, 2022Assignee: Yafei (Shanghai) Biopharmaceutical Co., Ltd.Inventors: Cheng Liu, Yuan Liu
-
Patent number: 11285169Abstract: Methods of reducing cytotoxicity of a chemotherapeutic agent to non-cancer cells by administering to a subject with cancer an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent, such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are provided. Example disclosed methods reduce cardiotoxicity. In one example, the methods include administering to a subject with cancer an effective amount of a CD47 antisense morpholino oligonucleotide and an anthracycline such as doxorubicin. Methods of increasing cytotoxicity of a chemotherapeutic agent in cancer cells by administering to a subject with a tumor an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are also provided. In some embodiments, the inhibitor of CD47 signaling is administered to the subject before, during, or after the administration of the DNA damaging agent.Type: GrantFiled: March 13, 2014Date of Patent: March 29, 2022Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: David D. Roberts, David R. Soto Pantoja
-
Patent number: 11253617Abstract: A method of preparing a 64Cu-BaBaSar-RGD2 solution is provided. The method includes lyophilizing a solution of BaBaSar-RGD2 and adding a 64Cu solution to the lyophilized BaBaSar-RGD2.Type: GrantFiled: November 30, 2018Date of Patent: February 22, 2022Assignee: University of Southern CaliforniaInventors: Shuanglong Liu, Peter Conti
-
Patent number: 11230576Abstract: The present invention relates to immunoglobulin (Ig) binding proteins comprising one or more Ig binding domains with amino acids selected from the group consisting at least of 1I, 11A, 11E, 11I, 35R, 35I, and 42L. The invention further relates to affinity matrices comprising the Ig binding proteins of the invention. The invention also relates to a use of these Ig binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the Ig binding proteins of the invention.Type: GrantFiled: August 7, 2017Date of Patent: January 25, 2022Assignee: Navigo Proteins GmbHInventors: Paul Knick, Erik Fiedler, Ulrich Haupts, Maren Meysing
-
Patent number: 11214624Abstract: Compositions and methods for inhibiting cancer cell metastasis and inflammation are disclosed. The methods generally involve administering to a subject a composition containing an agent that selectively inhibits the binding of p68 RNA helicase to calmodulin (CaM) in the cells.Type: GrantFiled: March 13, 2013Date of Patent: January 4, 2022Assignee: Proda Biotech LLCInventors: Zhi-Ren Liu, Haizhen Wang
-
Patent number: 11149061Abstract: A method of purifying an antifreeze protein (AFP) and methods of producing AFPs are disclosed. The method of purifying an AFP includes heating a crude AFP in an aqueous medium to a temperature and for a length of time sufficient to precipitate at least some thermally unstable proteins in the crude AFP and form a precipitate and a supernatant; and removing the precipitate from the supernatant. One method of producing an AFP includes collecting a crude source of the AFP; and purifying the AFP by the purification method. Another method of producing an AFP includes growing or culturing a host configured to express a recombinant AFP in a growth medium, and collecting a crude AFP from the host and/or the growth medium. The growth medium comprises water, a protein hydrolysate or other source of amino acids, a yeast extract, a biologically metabolizable C3-C6 polyol, and one or more phosphate salts.Type: GrantFiled: December 27, 2019Date of Patent: October 19, 2021Assignees: The Board of Trustees of the California State University, California State University, Los AngelesInventor: Xin Wen
-
Patent number: 11124547Abstract: Computational systems and methods are described for identifying new type-ll bacteriocins using a systemic consensus formula and other related criteria. Newly identified type-ll bacteriocin peptides are tested experimentally and show potent microbicidal activities. Further provided are the sequences of Newly identified type-ll bacteriocin peptides, and a method of treating an infection in a patient in need thereof, comprising administering to the patient an effective amount of a peptide comprising an amino acid sequence disclosed.Type: GrantFiled: May 10, 2018Date of Patent: September 21, 2021Assignee: THE LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATIONInventors: Nannette Y. Yount, Michael R. Yeaman
-
Patent number: 11090398Abstract: Methods and devices for sterilizing viscous peptide compositions which have shear thinning rheological properties at high concentrations.Type: GrantFiled: October 26, 2018Date of Patent: August 17, 2021Assignee: 3-D Matrix, Ltd.Inventors: Eun Seok Gil, Karl Patrick Gilbert
-
Patent number: 11066449Abstract: Improved electrically conductive pili were generated from a natural pilus protein from the microorganism Geobacter sulfurreducens. Substituting a tryptophan for the phenylalanine at position F51 and a tryptophan for the tyrosine at position Y57 of the pilus monomer substantially increased the conductivity of the pili and reduced their diameter to 1.5 nm. Substantial improvements in conductivity were also achieved by substituting an additional tyrosine, histidine, and phenylalanine in the pilus monomer to mimic the monomer of Geobacter metallireducens, but the pili retained the typical Geobacter sulfurreducens wild-type diameter of 3 nm.Type: GrantFiled: July 19, 2016Date of Patent: July 20, 2021Assignee: University of MassachusettsInventors: Derek R. Lovley, Nikhil Malvankar, Ramesh Adhikari, Yang Tan, Joy Ward, Kelly Nevin
-
Patent number: 11041013Abstract: The invention is related to peptide constructs, i.e.Type: GrantFiled: March 16, 2009Date of Patent: June 22, 2021Assignee: Cel-Sci CorporationInventor: Daniel H. Zimmerman
-
Patent number: 10975388Abstract: Provided are methods and compositions for delivering a nucleic acid, protein, and/or ribonucleoprotein payload to a cell. Also provided are delivery molecules that include a peptide targeting ligand conjugated to a protein or nucleic acid payload (e.g., an siRNA molecule), or conjugated to a charged polymer polypeptide domain (e.g., poly-arginine such as 9R or a poly-histidine such as 6H, and the like). The targeting ligand provides for (i) targeted binding to a cell surface protein, and (ii) engagement of a long endosomal recycling pathway. As such, when the targeting ligand engages the intended cell surface protein, the delivery molecule enters the cell (e.g., via endocytosis) but is preferentially directed away from the lysosomal degradation pathway.Type: GrantFiled: December 14, 2017Date of Patent: April 13, 2021Assignee: LIGANDAL, INC.Inventors: Andre Ronald Watson, Christian Foster
-
Patent number: 10954309Abstract: An Fc-binding polypeptide of improved alkali stability, comprising a mutant of an Fc-binding domain of Staphylococcus Protein A (SpA), as defined by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO 26 or SEQ ID NO 27, wherein at least the alanine residue at the position corresponding to position 42 in SEQ ID NO:4-7 has been mutated to arginine and/or wherein at least the aspartic acid residue at the position corresponding to position 37 in SEQ ID NO:4-7 has been mutated to glutamic acid.Type: GrantFiled: November 11, 2015Date of Patent: March 23, 2021Assignee: Cytiva BioProcess R&D ABInventors: Gustav Rodrigo, Tomas Bjorkman, Mats Ander
-
Patent number: 10899822Abstract: Compositions are disclosed that include D-amino acid peptides and that are capable of specifically binding to at least one autoantibody against a G-protein coupled receptor. The autoantibody is produced in a patient having or being predisposed to a disease, condition, or disorder, and the autoantibody is capable of binding to a specific epitope of the G-protein coupled receptor. Methods of production and use of said compositions are also disclosed.Type: GrantFiled: November 27, 2019Date of Patent: January 26, 2021Assignee: The Board of Regents of the University of OklahomaInventor: David C. Kem
-
Patent number: 10898542Abstract: The invention relates to a topical composition containing a variant of an OB-fold protein, and also to the process for preparing the same.Type: GrantFiled: December 24, 2019Date of Patent: January 26, 2021Assignee: AFFILOGICInventor: Olivier Kitten
-
Patent number: 10857258Abstract: Disclosed are novel peptides with adhesive properties to various materials of biological or non-biological origins.Type: GrantFiled: September 25, 2017Date of Patent: December 8, 2020Assignee: SEWON BIOTECHNOLOGY INC.Inventor: Won-Joon Yoon
-
Patent number: 10849959Abstract: An injectable aqueous formulation as well as a dosage form is disclosed for use in intra-articular injection of a specific peptide of SEQ ID NO: 1, whereby the joint pain at the injection site is relieved in the absence of detectable changes in joint cartilage formation, with pain particularly relieved under certain stress motions such as walking down stairs.Type: GrantFiled: June 12, 2018Date of Patent: December 1, 2020Assignee: ORTHOTROPHIX, INC.Inventors: Yoshinari Kumagai, Dawn McGuire, Meghan Miller, David Rosen
-
Patent number: 10849957Abstract: Making an initial evaluation of patient's joint pain when undergoing motions associated stress to the joint such as going up and down stairs, and injecting the patient with a peptide of SEQ ID No. 1, and thereafter evaluating the patient's joint pain when undergoing the same motion is disclosed.Type: GrantFiled: June 12, 2018Date of Patent: December 1, 2020Assignee: ORTHOTROPHIX, INC.Inventors: Yoshinari Kumagai, Dawn McGuire, Meghan Miller, David Rosen
-
Patent number: 10849958Abstract: Knee pain evaluation and management is carried out via intra-articular injections into a patient suffering from knee pain with the injection being comprised of water and a particularly defined peptide. After injection, knee pain is evaluated using a pain subscale such as Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) or Knee injury and Osteoarthritis Outcome Score (KOOS).Type: GrantFiled: June 12, 2018Date of Patent: December 1, 2020Assignee: ORTHOTROPHIX, INC.Inventors: Yoshinari Kumagai, Dawn McGuire, Meghan Miller, David Rosen
-
Patent number: 10842879Abstract: The invention provides a novel adrenomedullin derivative sustainable for a long period which is capable of substantially suppressing unwanted side effects while maintaining pharmacological effects of adrenomedullin. In an exemplary embodiment, the invention relates to a compound represented by formula (I): A-CH2—B (I) [wherein A is a modifying group comprising one or more polyethylene glycol groups, and B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, wherein the peptide moiety B is linked to the other moieties through a covalent bond of the nitrogen atom of the N-terminal ?-amino group of the peptide moiety B to the carbon atom of the methylene group] or a salt thereof, or a hydrate thereof.Type: GrantFiled: September 16, 2016Date of Patent: November 24, 2020Assignee: UNIVERSITY OF MIYAZAKIInventors: Kazuo Kitamura, Motoo Yamasaki
-
Patent number: 10799559Abstract: Methods of treating muscle wasting and other disorders with NOPE extracellular domain (ECD) polypeptides and NOPE ECD fusion molecules are provided.Type: GrantFiled: April 24, 2017Date of Patent: October 13, 2020Assignees: Five Prime Therapeutics, Inc., Glaxosmithkline Intellectual Property Development LimitedInventors: Aaron Curtis Hinken, Amy W. Hsu, Janine Powers, Warren James Rocque, Alan James Russell
-
Patent number: 10738094Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: June 30, 2016Date of Patent: August 11, 2020Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Andrea Mahr, Toni Weinschenk, Helen Hoerzer, Oliver Schoor, Jens Fritsche, Harpreet Singh
-
Patent number: 10696946Abstract: This invention relates to methods of expanding T regulatory cells through OX40L and Jagged-1 induced signaling. The methods can be used for treating autoimmune diseases.Type: GrantFiled: November 3, 2017Date of Patent: June 30, 2020Assignee: The Board of Trustees of the University of IllinoisInventor: Bellur Prabhakar
-
Patent number: 10697001Abstract: Provided herein are devices and methods for the capture or isolation of a biomarker from a biological sample. In several embodiments, the device comprises a loading region, a filter material, and a receiving region. In particular, in several embodiments, biological fluid is passed from the loading region through the filter material and into the receiving region, thereby resulting in capture or isolation of a biomarker.Type: GrantFiled: March 10, 2017Date of Patent: June 30, 2020Assignees: HITACHI CHEMICAL CO., LTD., HITACHI CHEMICAL CO. AMERICA, LTD.Inventors: Masato Mitsuhashi, Taku Murakami
-
Patent number: 10654915Abstract: Specific monoclonal antibodies and fragments including bispecific antibodies thereof that are crossreactive with multiple clades of influenza virus including both Group 1 and Group 2 representatives are disclosed. These antibodies are useful in controlling influenza epidemics and pandemics as well as in providing prophylactic or therapeutic protection against seasonal influenza.Type: GrantFiled: December 5, 2012Date of Patent: May 19, 2020Assignee: TRELLIS BIOSCIENCE, LLCInventors: Lawrence M. Kauvar, Stote Ellsworth, William Usinger, Krista Maureen McCutcheon, Minha Park
-
Patent number: 10617736Abstract: This invention relates to a method of increasing energy available to skeletal muscle cells comprising administering to the cells an effective amount of Tenurin C-terminal Associated Peptide (TCAP). The invention provides the use of TCAP to enhance muscle performance or recovery after injury as well as to prevent and/or treat a number of conditions including insulin resistance, type II diabetes, hypoxia and glycogen storage diseases.Type: GrantFiled: July 21, 2015Date of Patent: April 14, 2020Inventors: Yani Chen, David Lovejoy
-
Patent number: 10596265Abstract: A nanogel comprising a self-organizing peptide, a chitosan and polyethylene glycol is described.Type: GrantFiled: August 24, 2015Date of Patent: March 24, 2020Assignees: 3-D Matrix, Ltd., Tokyo University of Science FoundationInventors: Hidenori Otsuka, Daisuke Matsukuma
-
Patent number: 10548945Abstract: The invention relates to a topical composition containing a variant of an OB-fold protein, and also to the process for preparing the same.Type: GrantFiled: April 22, 2014Date of Patent: February 4, 2020Assignee: AFFILOGICInventor: Olivier Kitten
-
Patent number: 10544220Abstract: Bispecific antibodies directed to CD3 and CD20 and uses of such bispecific antibodies, in particular use thereof in the treatment of diseases in which specific targeting and T cell-mediated killing of cells that express CD20 is desired.Type: GrantFiled: January 8, 2016Date of Patent: January 28, 2020Assignee: GENMAB A/SInventors: Patrick Engelberts, Esther Breij, Rik Rademaker, Isil Altintas, David Satijn, Sandra Verploegen, Riemke Van Dijkhuizen Radersma, Edward Van Den Brink, Janine Schuurman, Paul Parren
-
Patent number: 10533039Abstract: The present invention provides peptides comprising a sequence of X?6X?5X?4X?3X?2X?1X1PX3X4PX6X7PGX10X11AX13X14X15X16LX18X19X20X21X22X23LX25X26 YLX29X30X31X32 (SEQ ID NO: 13) wherein the amino acids X?6, X?5, X?4, X?3, X?2, X?1, X1, X3, X4, X6, X7, X10, X11, X13, X14, X15, X16, X18, X19, X20, X21, X22, X25, X26, X29, X30, X31, and X32 are as defined herein. The present invention further provides pharmaceutical compositions comprising the peptides and methods of using the peptides for treating proliferative diseases such as cancer which are associated with Ras. Also provided are methods of screening a library of peptide dimers using a peptide dimer display technology.Type: GrantFiled: May 21, 2015Date of Patent: January 14, 2020Assignee: President and Fellows of Harvard CollegeInventors: Gregory L. Verdine, John Hanney McGee
-
Patent number: 10532040Abstract: The invention provides methods, uses and compounds for treating cancers. For example, certain embodiments provide a method for treating cancer in a mammal comprising administering to the mammal an effective amount of 3,5,7,8,4?-Pentahydroxyflavone, or a pharmaceutically acceptable salt thereof. Certain other embodiments of the invention provide methods for inactivating ornithine decarboxylase (ODC) in a cell comprising contacting the cell in vitro or in vivo with an effective amount of 3,5,7,8,4?-Pentahydroxyflavone, or a pharmaceutically acceptable salt thereof. The invention also provides a dermal product comprising 3,5,7,8,4?-Pentahydroxyflavone, or a pharmaceutically acceptable salt thereof, wherein the product prophylactically or therapeutically treats sunburn or other sun exposure and/or skin cancer in a mammal.Type: GrantFiled: November 19, 2012Date of Patent: January 14, 2020Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTAInventors: Ann M. Bode, Young-Yeon Cho, Zigang Dong, Dong Joon Kim